Exelixis (EXEL) Announces FDA Accepts for Priority Review sNDA for CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 65.31 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.31 | 52 Week High | $17.00 | |||
| Open | $65.31 | 52 Week Low | $3.55 | |||
| Day High | $65.31 | P/E | N/A | |||
| Day Low | $65.31 | EPS | $-1.33 | |||
| Volume | 149 | |||||
